{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:29:38Z","timestamp":1777922978974,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>\n                    This study evaluated the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    antimicrobial activity of telavancin against a large collection of Gram-positive pathogens of clinical importance, which were collected worldwide from 2015 through 2017, including methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MRSA), coagulase-negative staphylococci,\n                    <jats:italic toggle=\"yes\">Enterococcus<\/jats:italic>\n                    spp., \u03b2-hemolytic streptococci (BHS),\n                    <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                    , and viridans group streptococci (VGS). This report completes 7 years of continuous surveillance data for telavancin using the approved reference method for\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    testing methodology that includes the addition of polysorbate 80. For isolates collected from 2015 through 2017, telavancin exhibited potent activity against the following species and groups that have Clinical and Laboratory Standards Institute (CLSI)-approved interpretive criteria: MRSA (MIC\n                    <jats:sub>90<\/jats:sub>\n                    value, 0.06\u2009\u03bcg\/mL; 100% susceptible), vancomycin-susceptible\n                    <jats:italic toggle=\"yes\">Enterococcus faecalis<\/jats:italic>\n                    (MIC\n                    <jats:sub>90<\/jats:sub>\n                    value, 0.25\u2009\u03bcg\/mL; 99.9% susceptible), BHS (MIC\n                    <jats:sub>90<\/jats:sub>\n                    value, 0.03\u2009\u03bcg\/mL; 100% susceptible), and VGS (MIC\n                    <jats:sub>90<\/jats:sub>\n                    value, 0.03\u2009\u03bcg\/mL; 99.0% susceptible). Importantly, telavancin maintained excellent antimicrobial activity against multidrug-resistant subsets of these pathogen groups and against ceftaroline-nonsusceptible (telavancin MIC\n                    <jats:sub>90<\/jats:sub>\n                    value, 0.06\u2009\u03bcg\/mL; 100% susceptible) and ceftaroline-resistant (telavancin MIC\n                    <jats:sub>90<\/jats:sub>\n                    value, 0.12\u2009\u03bcg\/mL; 100% susceptible)\n                    <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                    isolates.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0104","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T14:14:50Z","timestamp":1581516890000},"page":"934-943","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Antimicrobial Activity of Telavancin Tested\n                    <i>In Vitro<\/i>\n                    Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015\u20132017)"],"prefix":"10.1177","volume":"26","author":[{"given":"Leonard R.","family":"Duncan","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ534"},{"key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diagmicrobio.2017.05.012","article-title":"Evaluation of the bactericidal activity of telavancin against Staphylococcus aureus using revised testing guidelines","volume":"89","author":"Sweeney D.","year":"2017","unstructured":"Sweeney D., , Shinabarger D.L, , Smart J.I, , Bruss J., , and Pillar C.M.. 2017. Evaluation of the bactericidal activity of telavancin against Staphylococcus aureus using revised testing guidelines. Diagn. Microbiol. Infect. Dis. 89:83\u201385.","journal-title":"Diagn. Microbiol. Infect. Dis"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_5_5_2","unstructured":"VIBAPackage Insert TIV. 2016. Package insert. Available at www.vibativ.com (accessed January2 2018)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1128\/AAC.00471-15","article-title":"Telavancin for acute bacterial skin and skin structure infections, a post hoc analysis of the phase 3 ATLAS trials in light of the 2013 FDA guidance","volume":"59","author":"Pushkin R.","year":"2015","unstructured":"Pushkin R., , Barriere S.L, , Wang W., , Corey G.R, , and Stryjewski M.E.. 2015. Telavancin for acute bacterial skin and skin structure infections, a post hoc analysis of the phase 3 ATLAS trials in light of the 2013 FDA guidance. Antimicrob. Agents. Chemother. 59:6170\u20136174.","journal-title":"Antimicrob. Agents. Chemother"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt490"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.633511"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40121-019-0255-0","article-title":"Telavancin in hospital-acquired and ventilator-associated pneumonia (HAP\/VAP) caused by Staphylococcus aureus: post hoc analysis of 2 randomized, controlled trials","volume":"8","author":"Niederman M.S.","year":"2019","unstructured":"Niederman M.S., , Lee P.C, , Barriere S.L, , Barnes C.N, , and Castaneda-Ruiz B.. 2019. Telavancin in hospital-acquired and ventilator-associated pneumonia (HAP\/VAP) caused by Staphylococcus aureus: post hoc analysis of 2 randomized, controlled trials. Infect. Dis. Ther. 8:445\u2013452.","journal-title":"Infect. Dis. Ther"},{"issue":"2","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/civ535","article-title":"The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"61","author":"Sandrock C.E.","year":"2015","unstructured":"Sandrock C.E., , and Shorr A.F.. 2015. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin. Infect. Dis. 61,(Suppl 2)::S79\u2013S86.","journal-title":"Clin. Infect. Dis"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.03.018"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_5_13_2","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2018. M07Ed11. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 11th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell D.J.","year":"2014","unstructured":"Farrell D.J., , Mendes R.E, , Rhomberg P.R, , and Jones R.N.. 2014. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob. Agents Chemother. 58:5547\u20135551.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_15_2","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2018. M100Ed28. Performance Standards for Antimicrobial Susceptibility Testing: 28th Informational Supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_5_16_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST).. 2018. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0 January 2018. Available at www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf (accessed January2 2018)."},{"key":"e_1_3_5_17_2","first-page":"702","article-title":"as determined by the revised susceptibility testing method","volume":"59","author":"Mendes R.E.","year":"2011","unstructured":"Mendes R.E., , Farrell D.J, , Sader H.S, , Flamm R.K, , and Jones R.N, . 2015. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in hospitals U.S (2011\u20132012) as determined by the revised susceptibility testing method. Antimicrob. Agents Chemother. 59:702\u2013706.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jgar.2014.12.003","article-title":"Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011\u20132013)","volume":"3","author":"Mendes R.E.","year":"2015","unstructured":"Mendes R.E., , Sader H.S, , Flamm R.K, , Farrell D.J, , and Jones R.N.. 2015. Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011\u20132013). J. Global Antimicrob. Res. 3:36\u201339.","journal-title":"J. Global Antimicrob. Res"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.12.011"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1179\/1973947815Y.0000000050","article-title":"Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011\u20132013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin","volume":"28","author":"Mendes R.E.","year":"2016","unstructured":"Mendes R.E., , Flamm R.K, , Farrell D.J, , Sader H.S, , and Jones R.N.. 2016. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011\u20132013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. J. Chemother. 28:83\u201388.","journal-title":"J. Chemother"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01867-15"},{"key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bjid.2013.11.005","article-title":"Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011)","volume":"18","author":"Flamm R.K.","year":"2014","unstructured":"Flamm R.K., , Sader H.S, , and Jones R.N.. 2014. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). Braz. J. Infect. Dis. 18:187\u2013195.","journal-title":"Braz. J. Infect. Dis"},{"key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America","volume":"77","author":"Sader H.S.","year":"2018","unstructured":"Sader H.S., , Flamm R.K, , Streit J.M, , Carvalhaes C.G, , and Mendes R.E.. 2018. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. Int. J. Infect. Dis. 77:82\u201386.","journal-title":"Int. J. Infect. Dis"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"e00777","DOI":"10.1128\/JCM.00777-18","article-title":"Evaluation of the revised ceftaroline disk diffusion breakpoints when testing a challenge collection of methicillin-resistant Staphylococcus aureus isolates","volume":"56","author":"Sader H.S.","year":"2018","unstructured":"Sader H.S., , Rhomberg P.R, , Doyle T.B, , Flamm R.K, , and Mendes R.E.. 2018. Evaluation of the revised ceftaroline disk diffusion breakpoints when testing a challenge collection of methicillin-resistant Staphylococcus aureus isolates. J. Clin. Microbiol. 56:e00777-18.","journal-title":"J. Clin. Microbiol"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:35:45Z","timestamp":1777667745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2019.0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1089\/mdr.2019.0104"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0104","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}